IPSEN (EPA:IPN) Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA
Transparency directive : regulatory news
13/02/2024 22:08
IPSEN's latest news
15/02/2024 10:00
13/02/2024 22:08
22/01/2024 23:00
07/12/2023 18:49
13/11/2023 22:30
06/10/2023 18:00
04/09/2023 07:00
01/09/2023 07:00
22/08/2023 18:00
16/08/2023 21:32
Other stories
29/04/2024 18:38
29/04/2024 18:54
29/04/2024 10:17
29/04/2024 16:01
29/04/2024 16:19
29/04/2024 14:49
29/04/2024 16:08
29/04/2024 16:26
29/04/2024 00:32
29/04/2024 14:13
29/04/2024 16:01
29/04/2024 18:41
29/04/2024 13:46
29/04/2024 17:38
29/04/2024 17:46
29/04/2024 19:08
29/04/2024 16:48
29/04/2024 16:48
29/04/2024 12:26
29/04/2024 14:08
29/04/2024 14:30
29/04/2024 19:30
29/04/2024 15:04
29/04/2024 19:44
29/04/2024 17:24
29/04/2024 18:03
29/04/2024 19:32
29/04/2024 15:23
29/04/2024 15:57
29/04/2024 14:48
28/04/2024 19:21
29/04/2024 12:00
29/04/2024 12:14
29/04/2024 14:39
28/04/2024 12:18
29/04/2024 19:43
29/04/2024 18:16